Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines.
We have reported recently that treatments combining injections of apoptotic bodies from tumor cells and interleukin 2 led to tumor regression and induced specific protection. In the present study, we show that tumor-bearing rats were cured with an 80% success rate by injection of antigen-presenting cells (APCs) that had phagocytosed apoptotic bodies derived from poorly immunogenic tumor cells, whereas phagocytic cells exposed to nonapoptotic tumor cell extracts were essentially without effect. In addition, curative vaccination using APCs that had phagocytosed apoptotic bodies generated a tumor-specific cytotoxic T-cell response and long-term protection from parental tumor challenge. Thus, systems using the processing and presentation of antigenic molecules by professional APCs after phagocytosis of apoptotic bodies appear to offer new possibilities for anticancer treatment.
Institut National de la Santé et de la Recherche Médicale 419, IFR 26, Biology Institute, Nantes, France.
F
F
Henry
O
O
Boisteau
L
L
Bretaudeau
B
B
Lieubeau
K
K
Meflah
M
M
Grégoire
D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000502:physiology / Q000637:transplantation*; D000951:Antigens, Neoplasm / Q000276:immunology; D017209:Apoptosis; D019496:Cancer Vaccines / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016233:Immunotherapy, Active; D008213:Lymphocyte Activation; D009000:Monocytes / Q000502:physiology / Q000637:transplantation; D010587:Phagocytosis; D051381:Rats; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines